hcmv

BAY-43-9695 is a non-nucleoside compound with anti-human cytomegalovirus (HCMV) activity. It is the major metabolite of BAY-38-4766.

BDCRB inhibits herpesvirus DNA maturation. BDCRB causes the HCMV terminase to skip the normal cleavage site and to continue to package DNA until a second cleavage site is encountered 30 kb further along the concatemer.

Ro 90-7501 is an amyloid β42 (Aβ42) protofibrillar and TPR-dependent PP5 inhibitor, a novel radiosensitizer for cervical cancer cells, which inhibits ATM phosphorylation, promotes apoptosis, and induces cell-cycle arrest. Ro 90-7501 also exhibits antiviral activity and potential anticancer activity by inhibiting ATM phosphorylation and DNA repair, and by inhibiting HCMV.

Penciclovir (BRL 39123) is a Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor. In HSV infected cells, penciclovir is phosphorylated by viral thymidine kinase and subsequently converted by cellular kinases into the active metabolite, penciclovir triphosphate, which competitively inhibits viral HSV polymerase by blocking deoxyguanosine triphosphate substrate binding. As a result, herpes viral DNA synthesis and replication are selectively inhibited.

1,4-Dihydroxynaphthalene A potent HSV-1 protease inhibitor with inhibitory effects on the HCMV protease, which can be used to study herpesviruses.

Tricin can inhibit human cytomegalovirus (HCMV) replication by inhibiting CDK9. Tricin inhibits the proliferation and invasion of C6 glioma cells via the upregulation of focal-adhesion-finase (FAK)-targeting microRNA-7.

SB-734117 inhibits productive replication of several HCMV strains. SB-734117 exhibited polypharmacology and was an inhibitor of several proteins from the AGC and CMCG kinase groups.

CMV-423 is an antiviral agent exhibiting effective in vitro activity against beta-herpesviruses, including Human Cytomegalovirus (HCMV), Human Herpesvirus 6 (HHV-6), and Human Herpesvirus 7 (HHV-7). It is utilized in antiviral research.

Bisindolylmaleimide IV is a protein kinase C (PKC) cell permeable inhibitor( IC50 : 0.10 - 0.55 μM)

Soyasaponin II has antiviral effects, it can inhibit the replication of human cytomegalovirus, influenza virus, and human immunodeficiency virus type 1.

Enocitabine is a nucleoside analog. Enocitabine inhibits the replication of human cytomegalovirus(HCMV) and it also has antileukemic and antiviral activities. Enocitabine is also a potent DNA replication inhibitor and a DNA chain terminator.

LDC4297 hydrochloride is a selective and efficient CDK7 inhibitor with broad-spectrum antiviral activity. It inhibits herpesvirus, adenovirus, poxvirus, retrovirus, and positive-strand RNA viruses. It can be used for research on viral infections.

pUL89 Endonuclease-IN-2 (Compound 15k) is a highly effective inhibitor of the pUL89 endonuclease of human cytomegalovirus (HCMV), demonstrating potent antiviral activities with an IC50 of 3.0 μM [1].

Letermovir (AIC246) (AIC246) is a novel anti-CMV compound (EC50: about 5 nM in fibroblast cells). It targets the pUL56 subunit of the viral terminase complex.

Maribavir (GW257406X) is an orally available benzimidazole riboside compound with activity against cytomegalovirus (CMV). Maribavir is a selective ATP competitor of the viral UL97 kinase, which is involved in viral nuclear maturation events, such as viral DNA assembly and movement of viral capsids from the nucleus of infected cells. Maribavir has activity against strains of CMV that are resistant to standard anti-CMV agents.

High affinity JNK inhibitor (Ki values are 25-50 nM). Inhibits JNK via competitive binding of the ATP-binding site of active, phosphorylated JNK. Exhibits > 40-fold selectivity for JNK over p38, ERK, IKK2, protein kinase C, Lck and ZAP70. Hepatoprotective. Also inhibits HCMV replication. Uehara et al (2004) c-Jun N-terminal kinase mediates hepatic injury after rat liver transplantation. Transplantation. 78 324 PMID:15316358 |Uehara et al (2005) JNK mediates hepatic ischemia reperfusion injury. J.Hepatol. 42 850 PMID:15885356 |Ma et al (2007) A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis. J.Am.Soc.Nephrol. 18 472 PMID:17202416 |Ma et al (2009) Blockade of the c-Jun amino terminal kinase prevents crescent formation and halts established anti-GBM glomerulonephritis in the rat. Lab.Invest. 89 470 PMID:19188913 |Zhang et al (2015) The c-Jun N-terminal kinase inhibitor SP600125 inhibits human cytomegalovirus replication. J.Med.Virol. 87 2135 PMID:26058558 |Vasilevskaya et al (2015) Inhibition of JNK sensitizes hypoxic colon cancer cells to DNA-damaging agents. Clin.Cancer.Res. 21 4143 PMID:26023085

Tomeglovir is a potent anti-CMV agent, inhibiting the processing of viral DNA-concatemers (IC50s: 0.34 0.039 μM for HCMV and MCMV).

Cidofovir diphosphate triethylamine, an active intracellular metabolite of Cidofovir, acts as a selective inhibitor of viral DNA polymerases. It exhibits inhibitory constants (K_i) of 6.6 μM for human cytomegalovirus (HCMV) DNA polymerase, 0.86 μM for herpes simplex virus-1 (HSV-1) DNA polymerase, and 1.4 μM for herpes simplex virus-2 (HSV-2) DNA polymerase, demonstrating its efficacy against these viral enzymes [1] [2].

pUL89 Endonuclease-IN-1 (Compound 13d), with an IC50 of 0.88 μM, is a potent inhibitor of human cytomegalovirus (HCMV) pUL89 endonuclease, demonstrating significant antiviral activity [1].

HBA(111-142), a C-terminal 32-mer fragment of alpha-hemoglobin, exhibits antibacterial activity against the ESKAPE panel of pathogens, forms amyloid fibrils, and possesses antiviral activities, notably inhibiting the measles virus and herpes viruses (HSV-1, HSV-2, HCMV) [1].

Fiztasovimab (NPC-21; EV2038), a fully human IgG1λ monoclonal antibody (mAb), targets human cytomegalovirus (hCMV). It exerts its neutralizing activity through binding to the antigenic domain 1 of glycoprotein B on the hCMV envelope, effectively inhibiting cell-to-cell transmission of hCMV [1].

DNA polymerase-IN-6 (Compound 27) exhibits inhibitory activity against DNA polymerase, with EC50 values of 0.33 µM for HCMV, 1.9 µM for HSV-1, 0.76 µM for HSV-2, and 0.066 µM for EBV.

ARP 101 is an effective selective matrix metalloproteinase-2 (MMP-2) inhibitor with anti-cancer activity. It induces the inhibition of HCMV through non-classical chelate 1 (SQSTM1) p62-Keap1-Nrf2 pathways and phosphorylation of the C-terminal domain of p62, regulating autophagy and inhibiting melanogenesis.